Weight Loss Vital in Treatment Of Polycystic Ovary Syndrome

VAIL, COLO. — Weight loss can go a long way toward improving the effects of hyperandrogenism in the adolescent with polycystic ovary syndrome, Dr. Patricia S. Simmons said at a meeting sponsored by the American Academy of Pediatrics.

“In the obese patient, this can be all she needs,” said Dr. Simmons, a past president of the North American Society for Pediatric and Adolescent Gynecology. “If their weight normalizes, usually their insulin levels and secondary hyperandrogenism will, too. It is certainly the most effective long-term treatment we have,” she added.

Polycystic ovary syndrome (PCOS) can be associated with a different pathophysiology in different individuals, said Dr. Simmons, a professor of pediatrics at the Mayo Clinic, Rochester, Minn. About 2%–3% of the general female population has PCOS, and it is present in about 53% of adolescents with chronic anovulation and amenorrhea.

One of the condition's hallmarks, hyperinsulinemia, is present in about 20% of adolescents with PCOS. Those individuals are more often obese, but that is not always the case. And in those individuals, the hyperinsulinemia helps drive the hyperandrogenism, which is why weight loss and improving insulin sensitivity can help, Dr. Simmons said.

Though in overweight individuals, weight loss alone may be treatment enough, others may also require drug therapy. The first-line drug for adolescents is an estrogen/progestin oral contraceptive, she said. The progestin inhibits luteinizing hormone, which leads to decreased androgen production by the ovaries, and the inhibition of adrenal androgen production. The estrogen elevates serum hormone-binding globulin, which further inhibits the effects of androgen.

Over the long term, this therapy protects the endometrium from the dysplasia and cancer associated with PCOS.

The oral contraceptive that many experts recommend is Yasmin, with ethinyl estradiol and drospirenone, because that progestin is actually an antiandrogen structurally similar to spironolactone, which itself is used as a treatment for PCOS in conjunction with an oral contraceptive, Dr. Simmons said.

However, there are no data to say that Yasmin is any better than other oral contraceptives in the management of PCOS, she noted.

Patients tend to appreciate oral contraceptive therapy because it improves their acne, makes their menstruation more regular, and stops the progression of their hirsutism.

“The health of adolescents with PCOS who are on oral contraceptives is better than that of their counterparts who are not on them, so it's an easy thing to prescribe with great confidence,” she added.

The diagnosis of PCOS in the adolescent can be difficult, especially since one would like to identify it early and begin addressing some of the long-term health impacts.

Oral contraceptives do not influence insulin levels, hence the necessity for weight loss in overweight PCOS patients. The use of oral glycemic agents in children and adolescents has not been rigorously studied and is recommended for use only in selective cases, she said.

Dr. Simmons had no conflicts of interest to report.

VAIL, COLO. — Weight loss can go a long way toward improving the effects of hyperandrogenism in the adolescent with polycystic ovary syndrome, Dr. Patricia S. Simmons said at a meeting sponsored by the American Academy of Pediatrics.

“In the obese patient, this can be all she needs,” said Dr. Simmons, a past president of the North American Society for Pediatric and Adolescent Gynecology. “If their weight normalizes, usually their insulin levels and secondary hyperandrogenism will, too. It is certainly the most effective long-term treatment we have,” she added.

Polycystic ovary syndrome (PCOS) can be associated with a different pathophysiology in different individuals, said Dr. Simmons, a professor of pediatrics at the Mayo Clinic, Rochester, Minn. About 2%–3% of the general female population has PCOS, and it is present in about 53% of adolescents with chronic anovulation and amenorrhea.

One of the condition's hallmarks, hyperinsulinemia, is present in about 20% of adolescents with PCOS. Those individuals are more often obese, but that is not always the case. And in those individuals, the hyperinsulinemia helps drive the hyperandrogenism, which is why weight loss and improving insulin sensitivity can help, Dr. Simmons said.

Though in overweight individuals, weight loss alone may be treatment enough, others may also require drug therapy. The first-line drug for adolescents is an estrogen/progestin oral contraceptive, she said. The progestin inhibits luteinizing hormone, which leads to decreased androgen production by the ovaries, and the inhibition of adrenal androgen production. The estrogen elevates serum hormone-binding globulin, which further inhibits the effects of androgen.

Over the long term, this therapy protects the endometrium from the dysplasia and cancer associated with PCOS.

The oral contraceptive that many experts recommend is Yasmin, with ethinyl estradiol and drospirenone, because that progestin is actually an antiandrogen structurally similar to spironolactone, which itself is used as a treatment for PCOS in conjunction with an oral contraceptive, Dr. Simmons said.

However, there are no data to say that Yasmin is any better than other oral contraceptives in the management of PCOS, she noted.

Patients tend to appreciate oral contraceptive therapy because it improves their acne, makes their menstruation more regular, and stops the progression of their hirsutism.

“The health of adolescents with PCOS who are on oral contraceptives is better than that of their counterparts who are not on them, so it's an easy thing to prescribe with great confidence,” she added.

The diagnosis of PCOS in the adolescent can be difficult, especially since one would like to identify it early and begin addressing some of the long-term health impacts.

Oral contraceptives do not influence insulin levels, hence the necessity for weight loss in overweight PCOS patients. The use of oral glycemic agents in children and adolescents has not been rigorously studied and is recommended for use only in selective cases, she said.

Dr. Simmons had no conflicts of interest to report.

VAIL, COLO. — Weight loss can go a long way toward improving the effects of hyperandrogenism in the adolescent with polycystic ovary syndrome, Dr. Patricia S. Simmons said at a meeting sponsored by the American Academy of Pediatrics.

“In the obese patient, this can be all she needs,” said Dr. Simmons, a past president of the North American Society for Pediatric and Adolescent Gynecology. “If their weight normalizes, usually their insulin levels and secondary hyperandrogenism will, too. It is certainly the most effective long-term treatment we have,” she added.

Polycystic ovary syndrome (PCOS) can be associated with a different pathophysiology in different individuals, said Dr. Simmons, a professor of pediatrics at the Mayo Clinic, Rochester, Minn. About 2%–3% of the general female population has PCOS, and it is present in about 53% of adolescents with chronic anovulation and amenorrhea.

One of the condition's hallmarks, hyperinsulinemia, is present in about 20% of adolescents with PCOS. Those individuals are more often obese, but that is not always the case. And in those individuals, the hyperinsulinemia helps drive the hyperandrogenism, which is why weight loss and improving insulin sensitivity can help, Dr. Simmons said.

Though in overweight individuals, weight loss alone may be treatment enough, others may also require drug therapy. The first-line drug for adolescents is an estrogen/progestin oral contraceptive, she said. The progestin inhibits luteinizing hormone, which leads to decreased androgen production by the ovaries, and the inhibition of adrenal androgen production. The estrogen elevates serum hormone-binding globulin, which further inhibits the effects of androgen.

Over the long term, this therapy protects the endometrium from the dysplasia and cancer associated with PCOS.

The oral contraceptive that many experts recommend is Yasmin, with ethinyl estradiol and drospirenone, because that progestin is actually an antiandrogen structurally similar to spironolactone, which itself is used as a treatment for PCOS in conjunction with an oral contraceptive, Dr. Simmons said.

However, there are no data to say that Yasmin is any better than other oral contraceptives in the management of PCOS, she noted.

Patients tend to appreciate oral contraceptive therapy because it improves their acne, makes their menstruation more regular, and stops the progression of their hirsutism.

“The health of adolescents with PCOS who are on oral contraceptives is better than that of their counterparts who are not on them, so it's an easy thing to prescribe with great confidence,” she added.

The diagnosis of PCOS in the adolescent can be difficult, especially since one would like to identify it early and begin addressing some of the long-term health impacts.

Oral contraceptives do not influence insulin levels, hence the necessity for weight loss in overweight PCOS patients. The use of oral glycemic agents in children and adolescents has not been rigorously studied and is recommended for use only in selective cases, she said.

Dr. Simmons had no conflicts of interest to report.